Connection | Profiles RNS

Search Result Details

Back to Search Results

This page shows the details of why an item matched the keywords from your search.

Search Results

JABBOUR, ELIAS JOSEPH

One or more keywords matched the following items that are connected to JABBOUR, ELIAS JOSEPH

Item Type	Name
Concept	MAP Kinase Signaling System
Concept	Protein-Tyrosine Kinases
Concept	p38 Mitogen-Activated Protein Kinases
Concept	Protein Kinase Inhibitors
Concept	Mitogen-Activated Protein Kinase Kinases
Concept	src-Family Kinases
Concept	Janus Kinase 1
Concept	Janus Kinase 2
Concept	Phosphatidylinositol 3-Kinases
Concept	Cyclin-Dependent Kinase Inhibitor p15
Concept	Janus Kinases
Concept	Cyclin-Dependent Kinase Inhibitor p57
Concept	fms-Like Tyrosine Kinase 3
Academic Article	Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
Academic Article	Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications.
Academic Article	Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.
Academic Article	Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.
Academic Article	Advances in the biology and therapy of patients with chronic myeloid leukaemia.
Academic Article	Treatment of Philadelphia-positive acute lymphocytic leukemia with tyrosine kinase inhibitors: What is the optimal regimen?
Academic Article	Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia.
Academic Article	Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy.
Academic Article	Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy.
Academic Article	Dasatinib for the treatment of chronic myeloid leukemia.
Academic Article	Treatment options for chronic myeloid leukemia.
Academic Article	Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management.
Academic Article	Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies.
Academic Article	Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate.
Academic Article	Dasatinib.
Academic Article	Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.
Academic Article	Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.
Academic Article	Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.
Academic Article	Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia.
Academic Article	Treatment of myelofibrosis in younger patients: to transplant or not?
Academic Article	Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules.
Academic Article	Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era.
Academic Article	Imatinib: high dose versus standard dose.
Academic Article	Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays.
Academic Article	Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia.
Academic Article	Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?
Academic Article	Mutant BCR-ABL clones in chronic myeloid leukemia.
Academic Article	Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Academic Article	Chronic myeloid leukemia: mechanisms of resistance and treatment.
Academic Article	Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.
Academic Article	EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience.
Academic Article	Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Academic Article	Tyrosine kinase inhibitors in acute and chronic leukemias.
Academic Article	Adherence to BCR-ABL inhibitors: issues for CML therapy.
Academic Article	10 years of progress in chronic myelogenous leukemia.
Academic Article	Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
Academic Article	Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia.
Academic Article	Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia.
Academic Article	Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options.
Academic Article	Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials.
Academic Article	Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.
Academic Article	Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.
Academic Article	Introduction: chronic myelogenous leukemia (CML).
Academic Article	Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
Academic Article	Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity.
Academic Article	Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs?
Academic Article	Understanding the role of mutations in therapeutic decision making for chronic myeloid leukemia.
Academic Article	Standard management of patients with chronic myeloid leukemia.
Academic Article	Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects.
Academic Article	Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors.
Academic Article	Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.
Academic Article	Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.
Academic Article	New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia.
Academic Article	Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib.
Academic Article	Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
Academic Article	The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Academic Article	The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?
Academic Article	Allogeneic stem cell transplantation for chronic myeloid leukemia resistant to tyrosine kinase inhibitors.
Academic Article	Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.
Academic Article	Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy.
Academic Article	Clinical roundtable monograph: Unmet needs in the management of chronic myelogenous leukemia.
Academic Article	Prognostic impact of RAS mutations in patients with myelodysplastic syndrome.
Academic Article	Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities.
Academic Article	Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy.
Academic Article	Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months.
Academic Article	Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors.
Academic Article	BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.
Academic Article	Selecting the best frontline treatment in chronic myeloid leukemia.
Academic Article	Current and emerging treatment options in chronic myeloid leukemia.
Academic Article	Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.
Academic Article	Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias.
Academic Article	Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?
Academic Article	Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
Academic Article	Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response.
Academic Article	Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
Academic Article	Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib.
Academic Article	Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.
Academic Article	Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: the role of the midlevel practitioner.
Academic Article	FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Academic Article	The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure.
Academic Article	Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib.
Academic Article	Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
Academic Article	New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance.
Academic Article	Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
Academic Article	Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure.
Academic Article	Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
Academic Article	Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.
Academic Article	Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?
Academic Article	Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure.
Academic Article	Suboptimal responses in chronic myeloid leukemia: implications and management strategies.
Academic Article	Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
Academic Article	A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Academic Article	Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).
Academic Article	Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience.
Academic Article	Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.
Academic Article	Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy.
Academic Article	Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome.
Academic Article	Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia.
Academic Article	Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia.
Academic Article	A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia.
Academic Article	A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes.
Academic Article	A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.
Academic Article	The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Academic Article	Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia?
Academic Article	A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy.
Academic Article	Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.
Academic Article	Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis.
Academic Article	Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.
Academic Article	The Effectiveness of Tyrosine Kinase Inhibitors and Molecular Monitoring Patterns in Newly Diagnosed Patients With Chronic Myeloid Leukemia in the Community Setting.
Academic Article	Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Academic Article	Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.
Academic Article	Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor.
Academic Article	Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors.
Academic Article	Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.
Academic Article	Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia.
Academic Article	Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous Leukemia.
Academic Article	Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Academic Article	Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials.
Academic Article	Chronic myeloid leukemia: First-line drug of choice.
Academic Article	Impact of Genetic Mutations and Health Plan Access to Therapies on Treatment Response and Drug Costs Related to Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myelogenous Leukemia.
Academic Article	Treatment options for tyrosine kinase inhibitor-resistant chronic myeloid leukemia
Academic Article	Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia
Academic Article	Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors
Academic Article	Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor
Academic Article	Management of tyrosine kinase inhibitors resistance
Academic Article	Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
Academic Article	Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy
Academic Article	The Effectiveness of Tyrosine Kinase Inhibitors and Molecular Monitoring Patterns in Newly Diagnosed Patients with Chronic Myeloid Leukemia in the Community Setting
Academic Article	Phase II trials of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
Academic Article	Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
Academic Article	Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia-a propensity score analysis
Academic Article	Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors
Academic Article	Impact of Genetic Mutations and Health Plan Access to Therapies on Treatment Response and Drug Costs Related to Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myelogenous Leukemia
Academic Article	Phase i trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome
Academic Article	Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies
Academic Article	Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes.
Academic Article	Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors.
Academic Article	Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.
Academic Article	Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia.
Academic Article	Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.
Academic Article	Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis.
Academic Article	Adult Acute Lymphoblastic Leukemia.
Academic Article	Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation.
Academic Article	Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults.
Academic Article	Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias.
Academic Article	Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship.
Academic Article	Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor.
Academic Article	A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia.
Academic Article	Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia.
Academic Article	Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Academic Article	Yes, treatment for CML should continue indefinitely.
Academic Article	Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia.
Academic Article	First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI.
Academic Article	Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting.
Academic Article	Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia?
Academic Article	Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors.
Academic Article	Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations.
Academic Article	Chronic lymphoproliferative disorder of NK-cells: A single-institution review with emphasis on relative utility of multimodality diagnostic tools.
Academic Article	Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives.
Academic Article	Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.
Academic Article	Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase.
Academic Article	Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring.
Academic Article	Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia.
Academic Article	Economic value of regular monitoring of response to treatment among US patients with chronic myeloid leukemia based on an economic model.
Academic Article	P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival.
Academic Article	Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation.
Academic Article	A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors.
Academic Article	Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia.
Academic Article	Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes.
Academic Article	Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience.
Academic Article	Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Academic Article	Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Academic Article	Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.
Academic Article	Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia.
Academic Article	"Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions"-Treatment of ALL.
Academic Article	Economic modeling to evaluate the impact of chronic myeloid leukemia therapy management on the oncology care model in the US.
Concept	TOR Serine-Threonine Kinases
Concept	Aurora Kinase B
Concept	Aurora Kinases
Academic Article	Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy.
Academic Article	Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series.
Academic Article	Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.
Academic Article	Therapy Options in Treating Acute Lymphoblastic Leukemia in Adults.
Academic Article	Long-term follow-up of lower dose dasatinib (50?mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.
Academic Article	Sudden blastic transformation in treatment-free remission chronic myeloid leukaemia.
Academic Article	Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.
Academic Article	Complexity of chronic-phase CML management after failing a second-generation TKI.
Academic Article	Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.
Academic Article	Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management.
Academic Article	Treatment-free remission in chronic myeloid leukemia.
Academic Article	FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.
Academic Article	Long-term results of a phase 2 trial of nilotinib 400?mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia.
Academic Article	Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.
Academic Article	Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Academic Article	Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias.
Academic Article	Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL.
Academic Article	Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions.
Academic Article	Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL.
Academic Article	Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML.
Academic Article	The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis.
Academic Article	Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
Academic Article	Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant.
Academic Article	The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes.
Academic Article	Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience.
Academic Article	Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia.
Academic Article	Acute myeloid leukemia: current progress and future directions.
Academic Article	Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors.
Academic Article	Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors.
Academic Article	A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.
Academic Article	Impact of frontline treatment approach on outcomes of myeloid blast phase CML.
Academic Article	Current Approaches to Philadelphia Chromosome-Positive B-Cell Lineage Acute Lymphoblastic Leukemia: Role of Tyrosine Kinase Inhibitor and Stem Cell Transplant.
Academic Article	SOHO State of the Art Updates & Next Questions: Intensive and Non-Intensive Approaches for Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Academic Article	The cure of leukemia through the optimist's prism.
Academic Article	Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification.
Academic Article	Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia.
Academic Article	Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors.
Academic Article	Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia.
Academic Article	Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML.
Academic Article	A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations.
Academic Article	Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
Academic Article	Real-life incidence of thrombotic events in leukemia patients treated with ponatinib.
Academic Article	A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase.
Academic Article	Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens: A Review.
Academic Article	Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia.
Academic Article	Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes.
Academic Article	Low-dose dasatinib 50?mg/day versus standard-dose dasatinib 100?mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis.
Academic Article	The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USA.
Academic Article	Incidence of adverse effects in patients receiving ponatinib with concomitant azole antifungals.
Academic Article	Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring.
Academic Article	Chronic myeloid leukemia without major molecular response after 2?years of treatment with tyrosine kinase inhibitor.
Academic Article	The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors.
Academic Article	Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia.
Academic Article	The emerging use of chemotherapy-free regimens in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Academic Article	Association between bariatric surgery and outcomes in chronic myeloid leukemia.
Academic Article	Management of chronic myeloid leukemia in 2023 - common ground and common sense.
Academic Article	Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class Rearrangements.
Academic Article	Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results.
Academic Article	Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era.
Academic Article	An Update on the Management of Advanced Phase Chronic Myeloid Leukemia.
Academic Article	Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-The Surveillance, Epidemiology, and End Results database, 2000-2019.
Academic Article	Aleukemic Chronic Myeloid Leukemia Without Neutrophilia and Thrombocytosis: A Report From the BCR::ABL1 Pathology Group.
Academic Article	Real-World Effectiveness of Dasatinib Versus Imatinib in Newly Diagnosed Patients With Chronic Myeloid Leukemia.
Academic Article	Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.

Search Criteria

Phosphotransferases